Ticagrelor, an oral antiplatelet medication, is widely available for prescription in various countries. It is marketed under the brand name Brilinta in the United States and Brilique in Europe and other regions [1]. The drug is used to prevent thrombotic events, such as heart attack and stroke, in patients with acute coronary syndrome or a history of myocardial infarction [2].
How is Ticagrelor typically prescribed?
Ticagrelor is usually prescribed by healthcare professionals, including cardiologists and general practitioners, for patients who have experienced a heart attack or have been diagnosed with certain types of cardiovascular disease. The typical starting dose is often 90 mg twice daily, which may be adjusted by a physician based on individual patient needs and response [2].
What is the generic availability of Ticagrelor?
As of late 2023 and early 2024, generic versions of ticagrelor are becoming available in several markets following patent expiries. This has the potential to lower the cost of the medication [3]. Information on specific generic approvals and launches can be found through resources like DrugPatentWatch.com [3].
When do Ticagrelor patents expire?
The patent expiry dates for ticagrelor vary by region due to different patent laws and intellectual property strategies. For example, in the United States, key patents related to ticagrelor have expired or are nearing expiry, opening the door for generic competition [3]. DrugPatentWatch.com tracks these patent expiries, providing detailed timelines for various pharmaceutical products.
What are the key uses and benefits of Ticagrelor?
Ticagrelor is primarily used to reduce the rate of cardiovascular events in patients with acute coronary syndrome (ACS). It works by inhibiting the P2Y12 receptor on platelets, thereby preventing blood clots from forming [2]. Clinical trials have demonstrated its efficacy in reducing risks such as heart attack, stroke, and cardiovascular death in these patient populations [1].
Are there alternatives to Ticagrelor?
Other antiplatelet medications are available and may be used as alternatives or in combination therapy, depending on the patient's condition. These include aspirin and clopidogrel. The choice of medication is determined by a physician considering factors like patient history, risk of bleeding, and efficacy for the specific cardiovascular condition [2].
What are the potential side effects of Ticagrelor?
Like all medications, ticagrelor can cause side effects. Common side effects include bleeding, shortness of breath, and bruising [1]. More serious side effects, though less common, can occur. Patients are advised to discuss any concerns about side effects with their doctor [2].